Munguia-Galaviz Francisco Javier, Miranda-Diaz Alejandra Guillermina, Gutierrez-Mercado Yanet Karina, Ku-Centurion Marco, Gonzalez-Gonzalez Ricardo Arturo, Portilla-de Buen Eliseo, Echavarria Raquel
Departamento de Fisiologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Division de Ciencias de la Salud, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzman 49000, Jalisco, Mexico.
Biomedicines. 2024 Aug 20;12(8):1908. doi: 10.3390/biomedicines12081908.
The Sigma-1 Receptor (Sigmar1) is a stress-activated chaperone and a promising target for pharmacological modulation due to its ability to induce multiple cellular responses. Yet, it is unknown how Sigmar1 is involved in cardiorenal syndrome type 4 (CRS4) in which renal damage results in cardiac dysfunction. This study explored the role of Sigmar1 and its ligands in a CRS4 model induced by unilateral ureteral obstruction (UUO) in male and female C57BL/6 mice. We evaluated renal and cardiac dysfunction markers, Sigmar1 expression, and cardiac remodeling through time (7, 12, and 21 days) and after chronically administering the Sigmar1 agonists PRE-084 (1 mg/kg/day) and SA4503 (1 mg/kg/day), and the antagonist haloperidol (2 mg/kg/day), for 21 days after UUO using colorimetric analysis, RT-qPCR, histology, immunohistochemistry, enzyme-linked immunosorbent assay, RNA-seq, and bioinformatics. We found that obstructive nephropathy induces Sigmar1 expression in the kidneys and heart, and that Sigmar1 stimulation with its agonists PRE-084 and SA4503 aggravates cardiac dysfunction and remodeling in both sexes. Still, their effects are significantly more potent in males. Our findings reveal essential differences associated with sex in the development of CRS4 and should be considered when contemplating Sigmar1 as a pharmacological target.
西格玛-1受体(Sigmar1)是一种应激激活伴侣蛋白,因其能够诱导多种细胞反应,故而成为药物调节的一个有前景的靶点。然而,目前尚不清楚Sigmar1如何参与4型心肾综合征(CRS4),在该综合征中,肾脏损伤会导致心脏功能障碍。本研究探讨了Sigmar1及其配体在雄性和雌性C57BL/6小鼠单侧输尿管梗阻(UUO)诱导的CRS4模型中的作用。我们通过比色分析、RT-qPCR、组织学、免疫组织化学、酶联免疫吸附测定、RNA测序和生物信息学,评估了UUO后不同时间点(7天、12天和21天)以及长期给予Sigmar1激动剂PRE-084(1毫克/千克/天)和SA4503(1毫克/千克/天)以及拮抗剂氟哌啶醇(2毫克/千克/天)21天后的肾功能和心脏功能障碍标志物、Sigmar1表达以及心脏重塑情况。我们发现,梗阻性肾病会诱导肾脏和心脏中Sigmar1的表达,并且用其激动剂PRE-084和SA4503刺激Sigmar1会加重两性的心脏功能障碍和重塑。不过,它们的作用在雄性中明显更强。我们的研究结果揭示了CRS4发展过程中与性别相关的本质差异,在将Sigmar1作为药物靶点进行考量时应予以考虑。